NCT04421352View on ClinicalTrials.gov

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

December 22, 2023

Study Completion Date

December 22, 2023

Conditions
Relapsed Small Cell Lung Cancer
Interventions
DRUG

CS1001

"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY